References
1. WHO (2021). Cardiovascular Diseases (CVDs). URL: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (date of access January 26, 2023)
2. Ference B.A., Ginsberg H.N., Graham I., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38 (32): 2459–72. DOI: https://www.doi.org/10.1093/eurheartj/ehx144
3. Sabatine M.S., Giugliano R.P., Keech A.C., et al. evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376 (18): 1713–22. DOI: https://www.doi.org/10.1056/NEJMoa1615664
4. Michos E.D., Sibley C.T., Baer J.T., et al. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol. 2012; 59 (23): 2058–64. DOI: https://www.doi.org/10.1016/j.jacc.2012.01.045
5. Silverman M.G., Ference B.A., Im K., et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016; 316 (12): 1289–97. DOI: https://www.doi.org/10.1001/jama.2016.13985
6. Toth P.P., Philip S., Hull M. et al. Elevated triglycerides (≥150 mg/dL) and high triglycerides (200-499 mg/dL) are significant predictors of new heart failure diagnosis: a real-world analysis of high-risk statin-treated patients. Vasc Health Risk Manag. 2019; 15: 533–8. DOI: https://www.doi.org/10.2147/VHRM.S221289
7. Generoso G., Janovsky C.C.P.S, Bittencourt M.S. Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis. Curr Opin Endocrinol Diabetes Obes. 2019; 26 (2): 109–16. DOI: https://www.doi.org/10.1097/MED.0000000000000468
8. Jørgensen A.B., Frikke-Schmidt R., West A.S., et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013; 34 (24): 1826–33. DOI: https://www.doi.org/10.1093/eurheartj/ehs431
9. Thomsen M., Varbo A., Tybjærg-Hansen A. et al. Low nonfasting triglycerides and reduced all-cause mortality: a Mendelian randomization study. Clin Chem. 2014; 60 (5): 737–46. DOI: https://www.doi.org/10.1373/clinchem.2013.219881
10. Nordestgaard L.T., Christoffersen M., Afzal S., et al. Triglycerides as a shared risk factor between dementia and atherosclerotic cardiovascular disease: a study of 125 727 individuals. Clin Chem. 2021; 67 (1): 245–55. DOI: https://www.doi.org/10.1093/clinchem/hvaa269
11. Hoogeveen R.C., Ballantyne C.M. Residual cardiovascular risk at low LDL: remnants, lipoprotein (a), and inflammation. Clinical Chemistry. 2021; 67 (1): 143–53.
12. Toth P.P., Fazio S., Wong N.D. et al. Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence. Diabetes Obes Metab. 2020; 22 (3): 279–89. DOI: https://www.doi.org/10.1111/dom.13921
13. Miller M., Cannon C.P., Murphy S.A., et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008; 51 (7): 724–30. DOI: https://www.doi.org/10.1016/j.jacc.2007.10.038
14. Teslovich T.M., Musunuru K., Smith A.V., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010; 466 (7307): 707–13. DOI: https://www.doi.org/10.1038/nature09270
15. Schunkert H., König I.R., Kathiresan S. et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011; 43 (4): 333–8. DOI: https://www.doi.org/10.1038/ng.784
16. Si S., Hou L., Chen X. et al. Exploring the causal roles of circulating remnant lipid profile on cardiovascular and cerebrovascular diseases: Mendelian randomization study. J Epidemiol. 2022; 32 (5): 205–14. DOI: https://www.doi.org/10.2188/jea.JE 20200305
17. Zhang B.H., Yin F., Qiao Y.N., et al. Triglyceride and triglyceride-rich lipoproteins in atherosclerosis. Front Mol Biosci. 2022; 9: 909151. DOI: https://www.doi.org/10.3389/fmolb.2022.909151
18. Mach F.., Baigent C, Catapano A.L. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41 (1): 111–88. DOI: https://www.doi.org/10.1093/eurheartj/ehz455
19. Visseren F.L.J., Mach F., Smulders Y.M., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42 (34): 3227–37. DOI: https://www.doi.org/10.1093/eurheartj/ehab484
20. Kukharchuk V.V., Ezhov M.V., Sergienko I.V. et al. Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2020). Eurasian heart journal. 2020; (2): 6–29. DOI: https://www.doi.org/10.38109/2225-1685-2020-2-6-29 (in Russian)
21. Russian clinical guidelines for lipid metabolism disorders, approved by the Russian Ministry of Health (2023). URL: https://cr.minzdrav.gov.ru/recomend/752_1 (in Russian)